Abstract
Muscimol, a psychoactive alkaloid from the Amanita muscaria mushroom, has long been regarded as a universal agonist for all GABA<sub>A</sub> receptor subtypes. However, recent pharmacological evidence suggests that its binding sites may be more heterogeneous than previously assumed. This study utilizes antipsychotic drugs—clozapine, loxapine, and chlorpromazine—as molecular probes to investigate the diversity of $^3$H-muscimol binding sites across different rat brain regions and recombinant receptor subtypes. Our results demonstrate that while the antagonist bicuculline displaces muscimol completely, antipsychotics exhibit partial and region-specific displacement. Computational modeling identifies the "Loop F" region of the $\alpha$ subunit as a key driver of this observed heterogeneity.
Introduction
GABA<sub>A</sub> receptors are pentameric ligand-gated ion channels that mediate fast inhibitory neurotransmission in the central nervous system. Composed of various subunits ($\alpha$1–6, $\beta$1–3, $\gamma$1–3, etc.), these receptors exhibit significant structural and functional diversity. Muscimol has traditionally been used as a gold-standard radioligand to label the orthosteric binding site across all subtypes. Recent observations, however, showed that antipsychotics like clozapine (CLZ) and loxapine (LOX) only partially displace $^3$H-muscimol in certain brain regions, suggesting the existence of multiple, pharmacologically distinct muscimol binding populations.
Methods
The study employed radioligand displacement assays using $^3$H-muscimol on membranes harvested from the rat hippocampus, cerebellum, thalamus, and striatum. Probes included bicuculline (BIC), LOX, CLZ, and chlorpromazine (CPZ). To isolate specific subtype responses, recombinant $\alpha$1$\beta$2, $\alpha$4$\beta$2, and $\alpha$6$\beta$2 receptors were expressed in HEK-293 cells. Structural insights were gained through in silico ligand analysis and molecular docking using AutoDock Vina, targeting high-resolution cryo-EM structures of GABA<sub>A</sub> receptors (PDB codes: 6HUK, 6X3S).
Results
Pharmacological assays revealed a consistent hierarchy of displacement potency across all brain regions: BIC > LOX > CLZ > CPZ. Crucially, while BIC achieved full displacement across all tested conditions, the antipsychotic probes showed varying degrees of partial displacement.
In contrast, clozapine (CLZ) displacement curves often plateaued, indicating that a significant fraction of muscimol binding sites remained insensitive to the drug. This partial displacement is a hallmark of the heterogeneity the researchers sought to map.
Regional analysis showed that LOX-sensitive sites were less prevalent in the cerebellum (~50% displacement) compared to the hippocampus and striatum. In the striatum, combining LOX and CPZ increased total displacement, suggesting these drugs target overlapping but distinct receptor populations. Computational docking indicated that the diversity in binding is largely driven by the "Loop F" region of the $\alpha$ subunit, which acts as a structural filter for larger ligands like CLZ.
Discussion
These findings challenge the "universal" binding model of muscimol. The observed heterogeneity suggests that local subunit composition and stoichiometry significantly influence the pharmacology of the orthosteric site. The identification of Loop F as a primary determinant of ligand selectivity provides a structural basis for understanding why certain drugs fail to displace muscimol from all receptor populations. Future research utilizing concatenated receptors—where subunits are physically linked in a specific order—will be essential to definitively map specific subunit arrangements to these distinct pharmacological profiles.
Summary updated